| Literature DB >> 24163815 |
Stavros Sfoungaristos1, Stavros Kontogiannis, Petros Perimenis.
Abstract
PURPOSE: To investigate the effect of preventing maximal urethral length until the level of verumontanum during radical prostatectomy on both oncologic and functional outcomes. PATIENTS AND METHODS: We recruited 329 patients, and they underwent an open radical prostatectomy by a single surgeon. The study cohort was randomized in 2 groups. A standard radical prostatectomy was performed in group A patients, while in group B the urethra was preserved until the level of verumontanum.Entities:
Mesh:
Year: 2013 PMID: 24163815 PMCID: PMC3791568 DOI: 10.1155/2013/426208
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Study cohort.
|
| 244 |
| Age (years), mean ± std | 66.2 ± 6.48 |
| PSA (ng/mL), mean ± std | 10.8 ± 9.22 |
| Clinical stage, | |
| T1c | 181 (74.2) |
| T2a | 45 (18.4) |
| T2b | 10 (4.1) |
| T2c | 8 (3.3) |
| Preoperative Gleason score, | |
| ≤6 | 123 (50.4) |
| 7 | 94 (38.5) |
| ≥8 | 27 (11.1) |
| Neurovascular spare, | |
| Yes | 141 (57.8) |
| No | 103 (42.2) |
| Pathological stage, | |
| T2a | 28 (11.5) |
| T2b | 9 (3.7) |
| T2c | 140 (57.4) |
| T3a | 39 (16.0) |
| T3b | 28 (11.5) |
| Postoperative Gleason score, | |
| ≤6 | 94 (38.5) |
| 7 | 110 (45.1) |
| ≥8 | 40 (16.4) |
| Surgical margins, | |
| Positive | 44 (18.0) |
| Negative | 200 (82.0) |
| Biochemical relapse, | |
| Yes | 39 (16.0) |
| No | 205 (84.0) |
Std: standard deviation.
Clinical and pathological findings regarding the preservation of urethra until the level of verumontanum.
| Group A | Group B |
| |
|---|---|---|---|
| Number of patients | 115 | 129 | |
| Age (years), mean ± std, IQR | 66.8 ± 6.68, 9 | 65.6 ± 6.28, 8 | 0.058† |
| PSA (ng/mL), mean ± std, IQR | 9.15 ± 4.15, 5.7 | 9.43 ± 5.82, 4.83 | 0.562† |
| Preoperative Gleason score, | 0.969‡ | ||
| ≤6 | 57 (49.6) | 66 (51.2) | |
| 7 | 45 (39.1) | 49 (38.0) | |
| ≥8 | 13 (11.3) | 14 (10.9) | |
| Pathological Gleason score, | 0.871‡ | ||
| ≤6 | 45 (39.1) | 49 (38.0) | |
| 7 | 50 (43.5) | 60 (46.5) | |
| ≥8 | 20 (17.4) | 20 (15.5) | |
| Pathological stage, | 0.433‡ | ||
| T2a | 12 (10.4) | 16 (12.4) | |
| T2b | 4 (3.48) | 5 (3.88) | |
| T2c | 63 (54.8) | 77 (59.7) | |
| T3a | 18 (15.7) | 21 (16.3) | |
| T3b | 18 (15.7) | 10 (7.75) | |
| Extracapsular disease, | 0.204‡ | ||
| Yes | 36 (31.3) | 31 (24.0) | |
| No | 79 (68.7) | 98 (76.0) | |
| Surgical margins, | 0.562‡ | ||
| Negative | 96 (83.5) | 104 (80.6) | |
| Positive | 19 (16.5) | 25 (19.4) | |
| Biochemical relapse, | 0.321‡ | ||
| Yes | 20 (17.4) | 19 (14.7) | |
| No | 95 (82.6) | 110 (85.3) | |
| Urgency at 1st month, | <0.001‡∗ | ||
| Yes | 71 (61.7) | 45 (34.9) | |
| No | 44 (38.3) | 84 (65.1) | |
| Nocturia at 1st month, | <0.001‡∗ | ||
| Yes | 74 (64.3) | 47 (36.4) | |
| No | 41 (35.7) | 82 (63.6) | |
| Incontinence at 1st month, | |||
| Urge | 29 (25.2) | 18 (14.0) | 0.026‡∗ |
| Stress | 62 (53.9) | 53 (41.1) | 0.045‡∗ |
| Incontinence at 1st year, | |||
| Urge | 12 (10.4) | 11 (8.53) | 0.611‡ |
| Stress | 24 (20.9) | 23 (17.8) | 0.548‡ |
| Pads/day, mean ± std, IQR | |||
| 1 month | 1.27 ± 0.91, 1 | 1.02 ± 0.81, 1 | 0.037†∗ |
| 3 months | 0.58 ± 0.74, 1 | 0.34 ± 0.63, 1 | 0.003†∗ |
| 6 months | 0.34 ± 0.62, 1 | 0.18 ± 0.44, 0 | 0.032†∗ |
| 12 months | 0.11 ± 0.44, 0 | 0.06 ± 0.27, 0 | 0.579† |
| ICIQ-SF, mean ± std, IQR | |||
| 1 month | 7.54 ± 5.42, 9 | 5.13 ± 4.39, 8 | 0.001†∗ |
| 3 months | 4.97 ± 6.08, 11 | 1.96 ± 3.96, 0 | <0.001†∗ |
| 6 months | 2.44 ± 4.63, 3 | 1.23 ± 3.20, 0 | 0.021†∗ |
| 12 months | 2.57 ± 5.54, 0 | 0.92 ± 3.31, 0 | 0.11† |
| IIQ-SF, mean ± std, IQR | |||
| 1 month | 5.99 ± 4.97, 9 | 4.46 ± 4.22, 8 | 0.021†∗ |
| 3 months | 3.48 ± 4.36, 7 | 1.35 ± 2.70, 0 | <0.001†∗ |
| 6 months | 1.56 ± 3.34, 0 | 0.81 ± 2.51, 0 | 0.057† |
| 12 months | 0.63 ± 2.56, 0 | 0.38 ± 1.62, 0 | 0.590† |
†Mann-Whitney U test, ‡Chi-square test, *statistically significant, std: standard deviation, IQR: interquartile range, ICIQ-SF: international consultation on incontinence questionnaire-short form, and IIQ-SF: incontinence impact questionnaire-short form.
Figure 1Positive surgical margins.
Figure 2Rate of urgency, nocturia, stress, and urge incontinence 1 month after surgery.
Figure 3ICIQ-SF questionnaire.
Figure 4IIQ-SF questionnaire.